Myasthenia gravis

Patients should be followed in neurology clinics. Frequency of clinic visits (typically every 3 to 12 months) depends on the severity of the disease, need for drug therapy monitoring, and presence of systemic comorbidities.

Patients should be asked about:[97]Farrugia ME, Goodfellow JA. A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature. Front Neurol. 2020 Jul 7;11:604. https://www.frontiersin.org/articles/10.3389/fneur.2020.00604/full http://www.ncbi.nlm.nih.gov/pubmed/32733360?tool=bestpractice.com [159]Ruiter AM, Verschuuren JJGM, Tannemaat MR. Fatigue in patients with myasthenia gravis. A systematic review of the literature. Neuromuscul Disord. 2020 Aug;30(8):631-9. https://www.nmd-journal.com/article/S0960-8966(20)30160-7/fulltext http://www.ncbi.nlm.nih.gov/pubmed/32718868?tool=bestpractice.com

• Any muscle fatigue and/or weakness interfering with the activities of daily living

• Central fatigue (lack of energy, physically and/or mentally), as this is common in patients with MG and adversely affects quality of life

• Swallowing and breathing

• Infections

• Adverse effects and tolerability of drug therapy.

Immunosuppressive and immunomodulatory therapy should be monitored as indicated.